Erythromycin Market Top Companies Trends, Product Innovations, Technology and Revenue Status: Coherent Market Insights

SEATTLE, April 01, 2021, (PHARMIWEB) — Global Erythromycin Market

Erythromycin is an antibiotic used to treat several kinds of bacterial infection. Erythromycin topical preparations are largely used on the skin to help control acne. The antibiotic drug is also used in combination with other medicines and applied topically or taken orally, for the effective treatment of bacterial infections. The common side effects of erythromycin include nausea, loss of appetite, diarrhea, and abdominal pain. Erythromycin prevents bacterial cells from growing and multiplying by impairing their ability to make proteins. The drug is widely used for treating chest infections, such as pneumonia; skin problems, such as acne and rosacea; dental abscesses; and sexually transmitted infections.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1780

Global Erythromycin Market Dynamics

Pharmaceutical manufacturers are focused on increasing access to affordable medications to provide novel options for patients and pharmacists, thereby addressing the limited availability of erythromycin tablets. This is apparently augmenting the global erythromycin market growth. For instance, in March 2018, Amneal Pharmaceuticals received the FDA approval for Erythromycin Tablets USP (250 mg and 500 mg doses). The drug is a therapeutic equivalent of the reference-listed drug (RLD) erythromycin tablets from Arbor Pharmaceuticals, and is the only other immediate-release oral tablet available. In September 2016, ANI Pharmaceuticals, Inc. launched Erythromycin Ethylsuccinate for oral suspension (200mg/5mL, which is indicated as a treatment for various infections, including upper and lower respiratory infections, skin and soft tissue infections, genitourinary infection, Legionnaires disease, pertussis, and others.

Surging prevalence of various infectious diseases, including respiratory tract infections, is a prominent aspect projected to augment the global market growth in the near future. In a study conducted by Bill & Melinda Gates Foundation in 2015, it was revealed that around 2.74 million deaths caused by lower respiratory tract infections are recorded every year globally. This is further expected to increase the worldwide adoption of antibiotics like erythromycin.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3mbmhdT

On the other hand, signs of allergic reaction to erythromycin, such as swelling of the mouth, face, lips, tongue, or throat, and increasing availability of alternatives, such as azithromycin, are significant factors hindering market growth. Furthermore, pregnant women are warned from using these antibiotic pills as the researchers from Great Ormond Street Hospital and University College London, 2015, stated that erythromycin pills are linked with higher risks of epilepsy and cerebral palsy in the newborn babies.

Global Erythromycin Market – Regional Dynamics

The North America erythromycin market is expected to hold a dominant position over the forecast period, owing to the rising number of regulatory approvals of drugs to address the unmet medical needs of patients, and growing prevalence of skin and soft tissue infections. For instance, in November, 2016, Rising Pharmaceuticals, Inc.—a subsidiary of Aceto Corporation—launched Erythromycin and Benzoyl Peroxide Topical Gel USP, 3-5% an FDA-approved generic version of Valeant International’s Benzamycin Gel, 3-5%. According to the Division of Infectious Diseases, Los Angeles BioMedical Research Center, 2015, skin and soft tissue infections (SSTIs) are a common reason to seek medical care in the U.S. as they can lead to complications with significant morbidity, including hospitalization, surgical procedures, or even death.

Global Erythromycin Market- Competitive Analysis

The leading players operating in the global erythromycin market include ANI Pharmaceuticals, Akorn, Inc., Aceto Corporation, Genesis Pharmaceuticals, Teligent, Inc., Abbvie, Inc., Abbott Laboratories, Pfizer, Inc., Sanofi-Aventis, and Allergan, Plc. These manufactures are deeply focused on the development, manufacturing, and marketing of multi-source and branded pharmaceuticals. For instance, in July 2017, Teligent, Inc., a generic pharmaceutical company, received approval for its abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Erythromycin Topical Gel USP, 2%. Furthermore, in 2010, Akorn, Inc. received the U.S. Food and Drug Administration (FDA) approval for the company’s ANDA supplement for its Erythromycin Ophthalmic Ointment USP 3.5 g.

To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1780

Market Taxonomy

On the basis of formulation:

• Gel
• Tablet
• Topical Solution
• Ointment
• Others

On the basis of therapeutic indication:

• Respiratory Tract Infections
• Eye Infections
• Ear Infections
• Skin and Soft Tissue Infections
• Gastro-intestinal Infections
• Others

By distribution channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Table of Content

Global Erythromycin Market Research Report
Section 1: Global Erythromycin Industry Overview
Section 2: Global Economic Impact on Erythromycin Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Erythromycin Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Erythromycin Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737